Evidence map›Paper›PMID 40024686›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Complete Remission with Nivolumab Monotherapy of Advanced Gastric Neuroendocrine Carcinoma.

Koichiro Tajima, Yuichi Shimodate, Hirokazu Mouri, Yoshio Nagahisa, Shinichi Nishina, Motowo Mizuno

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Koichiro TajimaDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan.
Yuichi ShimodateDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan.
Hirokazu MouriDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan.
Yoshio NagahisaDepartment of Surgery, Kurashiki Central Hospital, Japan.
Shinichi NishinaDepartment of Surgery, Kurashiki Central Hospital, Japan.
Motowo MizunoDepartment of Gastroenterology and Hepatology, Kurashiki Central Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 77-year-old man with large-cell gastric neuroendocrine carcinoma underwent palliative total gastrectomy after 10 cycles of carboplatin and etoposide chemotherapy for severe tumor bleeding. Despite a histological grade 0 therapeutic effect, the remnant lesions were treated with paclitaxel and ramucirumab, but progression occurred after two cycles. Nivolumab monotherapy was then initiated, resulting in complete remission after three cycles. Nivolumab was discontinued because of immune-related psoriasis, but complete remission persisted for at least 16 months. This is the first reported case of nivolumab monotherapy achieving complete remission in gastric neuroendocrine carcinoma with the patient surviving 28 months.

Indexed as

Antineoplastic Agents, ImmunologicalCarcinoma, NeuroendocrineNivolumabStomach NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsGastrectomyHumansMaleRemission InductionTreatment OutcomeAntineoplastic Agents, ImmunologicalNivolumabcarboplatingastric cancerneuroendocrine carcinomanivolumabpaclitaxelramucirumab

Identifiers

PMID40024686
PMCPMC11949651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.